A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1995-05

AUTHORS

Helen W. Pass, Barbara K. Temeck, Karen Kranda, Seth M. Steinberg, Harvey I. Pass

ABSTRACT

Background: The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy. We initiated a phase II trial of immunochemotherapy with cisplatinum (25 mg/m2 four times weekly), interferon-α (5 mU/m2 s.c. three times weekly), and tamoxifen (20 mg orally twice a day for 35 days) (CIT) based on in vitro and in vivo data suggesting interrelating efficacy of this combination.Methods: Since July 1991, 36 patients have been evaluable for response after receiving one to five cycles of CIT. Ten additional patients had debulking surgery followed by two cycles of postoperative adjuvant CIT commencing a mean of 6 weeks after surgery.Results: Toxicity was acceptable (4% grade III/IV). One treatment-related death (2%) occurred, from myocardial infarction. A 19% partial response rate, objectively quantified using three-dimensional computerized tomographic (CT) measurement of solid disease volume, was recorded. The median survival for the seven responders was 14.7 months, whereas that of the nonresponders was 8 months (p2=0.2). Median survival for the entire group was 8.7 months. Preoperative size, platelet count >360,000/ml, and nonepithelial histology were associated with shortened survival.Conclusions: The CIT regimen has some activity in MPM and can be delivered after debulking resection. In good-risk patients, as defined by favorable prognostic factors, a randomized trial using this combination may be warranted. More... »

PAGES

214-220

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02307026

DOI

http://dx.doi.org/10.1007/bf02307026

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018395434

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7641017


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mesothelioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pass", 
        "givenName": "Helen W.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Temeck", 
        "givenName": "Barbara K.", 
        "id": "sg:person.01306041342.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kranda", 
        "givenName": "Karen", 
        "id": "sg:person.01032321717.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steinberg", 
        "givenName": "Seth M.", 
        "id": "sg:person.014210640617.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pass", 
        "givenName": "Harvey I.", 
        "id": "sg:person.0763326335.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00255753", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040954660", 
          "https://doi.org/10.1007/bf00255753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00194542", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052242345", 
          "https://doi.org/10.1007/bf00194542"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1995-05", 
    "datePublishedReg": "1995-05-01", 
    "description": "Background: The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy. We initiated a phase II trial of immunochemotherapy with cisplatinum (25 mg/m2 four times weekly), interferon-\u03b1 (5 mU/m2 s.c. three times weekly), and tamoxifen (20 mg orally twice a day for 35 days) (CIT) based on in vitro and in vivo data suggesting interrelating efficacy of this combination.Methods: Since July 1991, 36 patients have been evaluable for response after receiving one to five cycles of CIT. Ten additional patients had debulking surgery followed by two cycles of postoperative adjuvant CIT commencing a mean of 6 weeks after surgery.Results: Toxicity was acceptable (4% grade III/IV). One treatment-related death (2%) occurred, from myocardial infarction. A 19% partial response rate, objectively quantified using three-dimensional computerized tomographic (CT) measurement of solid disease volume, was recorded. The median survival for the seven responders was 14.7 months, whereas that of the nonresponders was 8 months (p2=0.2). Median survival for the entire group was 8.7 months. Preoperative size, platelet count >360,000/ml, and nonepithelial histology were associated with shortened survival.Conclusions: The CIT regimen has some activity in MPM and can be delivered after debulking resection. In good-risk patients, as defined by favorable prognostic factors, a randomized trial using this combination may be warranted.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf02307026", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "malignant pleural mesothelioma", 
      "phase II trial", 
      "median survival", 
      "pleural mesothelioma", 
      "treatment-related deaths", 
      "good-risk patients", 
      "partial response rate", 
      "favorable prognostic factor", 
      "computerized tomographic measurements", 
      "nonepithelial histology", 
      "adjuvant immunochemotherapy", 
      "maximal cytoreduction", 
      "prognostic factors", 
      "additional patients", 
      "disease volume", 
      "preoperative size", 
      "platelet count", 
      "myocardial infarction", 
      "response rate", 
      "immunochemotherapy", 
      "entire group", 
      "surgery", 
      "patients", 
      "trials", 
      "months", 
      "mesothelioma", 
      "survival", 
      "vivo data", 
      "standard techniques", 
      "tomographic measurements", 
      "cytoreduction", 
      "nonresponders", 
      "regimen", 
      "resection", 
      "infarction", 
      "chemotherapy", 
      "cisplatinum", 
      "tamoxifen", 
      "radiotherapy", 
      "CIT", 
      "interferon", 
      "responders", 
      "histology", 
      "weeks", 
      "efficacy", 
      "death", 
      "treatment", 
      "toxicity", 
      "counts", 
      "group", 
      "response", 
      "combination", 
      "factors", 
      "activity", 
      "rate", 
      "volume", 
      "cycle", 
      "use", 
      "data", 
      "feasibility", 
      "means", 
      "technique", 
      "size", 
      "measurements", 
      "II trial", 
      "cycles of CIT", 
      "postoperative adjuvant CIT", 
      "adjuvant CIT", 
      "three-dimensional computerized tomographic (CT) measurement", 
      "solid disease volume", 
      "CIT regimen", 
      "primary immunochemotherapy"
    ], 
    "name": "A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction", 
    "pagination": "214-220", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018395434"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02307026"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7641017"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02307026", 
      "https://app.dimensions.ai/details/publication/pub.1018395434"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_275.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf02307026"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'


 

This table displays all metadata directly associated to this object as RDF triples.

240 TRIPLES      22 PREDICATES      118 URIs      108 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02307026 schema:about N017b07a9483d45fbbd8a3224f953cdd5
2 N148db852a2d24dfcada600ef836112c6
3 N1cef0bf487ce4d5dad0e85769456c42c
4 N51124e214d5f4dc69633b2c7443aae6a
5 N5eef36a3f40848cd8738f6e81e48dd99
6 N6bc1a1a893314cc393ea2dde016051b0
7 N6e59df042a4f4cd3952f6e9ffe18ac7b
8 N71a7b67e655642beb9ffcf98ab87a9ba
9 N7eb9ea543b2540d1887a1510ec7483be
10 N849362cb458f4ac6a7884f9d295a05df
11 Na013c9014317407ca3034e701506510c
12 Nc167b46382b7408aab9a0f7931702625
13 Ndcaaeefda5634607aa116ac559e4252e
14 Ne94ef49ac71f4e348e44daf7e23d16ff
15 Nef5d9ebf4dfd43a59e41c3fd46aac182
16 Nfbf1150d5d3d4f5d9a293dfd817f305b
17 Nfdc35204645046e5a9a27a84b94c60d6
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Na360da56bbfa44d792e5095d2d380fce
21 schema:citation sg:pub.10.1007/bf00194542
22 sg:pub.10.1007/bf00255753
23 schema:datePublished 1995-05
24 schema:datePublishedReg 1995-05-01
25 schema:description Background: The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy. We initiated a phase II trial of immunochemotherapy with cisplatinum (25 mg/m2 four times weekly), interferon-α (5 mU/m2 s.c. three times weekly), and tamoxifen (20 mg orally twice a day for 35 days) (CIT) based on in vitro and in vivo data suggesting interrelating efficacy of this combination.Methods: Since July 1991, 36 patients have been evaluable for response after receiving one to five cycles of CIT. Ten additional patients had debulking surgery followed by two cycles of postoperative adjuvant CIT commencing a mean of 6 weeks after surgery.Results: Toxicity was acceptable (4% grade III/IV). One treatment-related death (2%) occurred, from myocardial infarction. A 19% partial response rate, objectively quantified using three-dimensional computerized tomographic (CT) measurement of solid disease volume, was recorded. The median survival for the seven responders was 14.7 months, whereas that of the nonresponders was 8 months (p2=0.2). Median survival for the entire group was 8.7 months. Preoperative size, platelet count >360,000/ml, and nonepithelial histology were associated with shortened survival.Conclusions: The CIT regimen has some activity in MPM and can be delivered after debulking resection. In good-risk patients, as defined by favorable prognostic factors, a randomized trial using this combination may be warranted.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N2f43142c55ee49728cb8e8e5a49c88c1
30 N7b09c465777c493484fda1b26941c237
31 sg:journal.1105545
32 schema:keywords CIT
33 CIT regimen
34 II trial
35 activity
36 additional patients
37 adjuvant CIT
38 adjuvant immunochemotherapy
39 chemotherapy
40 cisplatinum
41 combination
42 computerized tomographic measurements
43 counts
44 cycle
45 cycles of CIT
46 cytoreduction
47 data
48 death
49 disease volume
50 efficacy
51 entire group
52 factors
53 favorable prognostic factor
54 feasibility
55 good-risk patients
56 group
57 histology
58 immunochemotherapy
59 infarction
60 interferon
61 malignant pleural mesothelioma
62 maximal cytoreduction
63 means
64 measurements
65 median survival
66 mesothelioma
67 months
68 myocardial infarction
69 nonepithelial histology
70 nonresponders
71 partial response rate
72 patients
73 phase II trial
74 platelet count
75 pleural mesothelioma
76 postoperative adjuvant CIT
77 preoperative size
78 primary immunochemotherapy
79 prognostic factors
80 radiotherapy
81 rate
82 regimen
83 resection
84 responders
85 response
86 response rate
87 size
88 solid disease volume
89 standard techniques
90 surgery
91 survival
92 tamoxifen
93 technique
94 three-dimensional computerized tomographic (CT) measurement
95 tomographic measurements
96 toxicity
97 treatment
98 treatment-related deaths
99 trials
100 use
101 vivo data
102 volume
103 weeks
104 schema:name A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction
105 schema:pagination 214-220
106 schema:productId N1755513143ff4981bea8cb8c3fe4fa87
107 N9301c8e1afd34807b9e6203af3838a8f
108 Nc8c189de180e459a93948f6dd67f65f7
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018395434
110 https://doi.org/10.1007/bf02307026
111 schema:sdDatePublished 2022-01-01T18:08
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N5aa56e5a31df4d369d8914c401669885
114 schema:url https://doi.org/10.1007/bf02307026
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N017b07a9483d45fbbd8a3224f953cdd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Interferon-alpha
120 rdf:type schema:DefinedTerm
121 N148db852a2d24dfcada600ef836112c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Aged
123 rdf:type schema:DefinedTerm
124 N1755513143ff4981bea8cb8c3fe4fa87 schema:name doi
125 schema:value 10.1007/bf02307026
126 rdf:type schema:PropertyValue
127 N1cef0bf487ce4d5dad0e85769456c42c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Female
129 rdf:type schema:DefinedTerm
130 N2f43142c55ee49728cb8e8e5a49c88c1 schema:volumeNumber 2
131 rdf:type schema:PublicationVolume
132 N44c867a5544d4547bed2291dc35afae3 rdf:first sg:person.01032321717.09
133 rdf:rest Nd5de65567abb480ba65814296f13c8b4
134 N468afb04059c4b0c955641688f90276e schema:affiliation grid-institutes:grid.48336.3a
135 schema:familyName Pass
136 schema:givenName Helen W.
137 rdf:type schema:Person
138 N51124e214d5f4dc69633b2c7443aae6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Pleural Neoplasms
140 rdf:type schema:DefinedTerm
141 N551bd84c7683495d970ea72aa512ec12 rdf:first sg:person.01306041342.14
142 rdf:rest N44c867a5544d4547bed2291dc35afae3
143 N5aa56e5a31df4d369d8914c401669885 schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 N5eef36a3f40848cd8738f6e81e48dd99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Tamoxifen
147 rdf:type schema:DefinedTerm
148 N6bc1a1a893314cc393ea2dde016051b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Male
150 rdf:type schema:DefinedTerm
151 N6e59df042a4f4cd3952f6e9ffe18ac7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Adult
153 rdf:type schema:DefinedTerm
154 N71a7b67e655642beb9ffcf98ab87a9ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Middle Aged
156 rdf:type schema:DefinedTerm
157 N7a6f1644882b4bb7a08e35490a521046 rdf:first sg:person.0763326335.92
158 rdf:rest rdf:nil
159 N7b09c465777c493484fda1b26941c237 schema:issueNumber 3
160 rdf:type schema:PublicationIssue
161 N7eb9ea543b2540d1887a1510ec7483be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Immunotherapy
163 rdf:type schema:DefinedTerm
164 N849362cb458f4ac6a7884f9d295a05df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Humans
166 rdf:type schema:DefinedTerm
167 N9301c8e1afd34807b9e6203af3838a8f schema:name pubmed_id
168 schema:value 7641017
169 rdf:type schema:PropertyValue
170 Na013c9014317407ca3034e701506510c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Mesothelioma
172 rdf:type schema:DefinedTerm
173 Na360da56bbfa44d792e5095d2d380fce rdf:first N468afb04059c4b0c955641688f90276e
174 rdf:rest N551bd84c7683495d970ea72aa512ec12
175 Nc167b46382b7408aab9a0f7931702625 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Cisplatin
177 rdf:type schema:DefinedTerm
178 Nc8c189de180e459a93948f6dd67f65f7 schema:name dimensions_id
179 schema:value pub.1018395434
180 rdf:type schema:PropertyValue
181 Nd5de65567abb480ba65814296f13c8b4 rdf:first sg:person.014210640617.24
182 rdf:rest N7a6f1644882b4bb7a08e35490a521046
183 Ndcaaeefda5634607aa116ac559e4252e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Proportional Hazards Models
185 rdf:type schema:DefinedTerm
186 Ne94ef49ac71f4e348e44daf7e23d16ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Feasibility Studies
188 rdf:type schema:DefinedTerm
189 Nef5d9ebf4dfd43a59e41c3fd46aac182 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Survival Analysis
191 rdf:type schema:DefinedTerm
192 Nfbf1150d5d3d4f5d9a293dfd817f305b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Chemotherapy, Adjuvant
194 rdf:type schema:DefinedTerm
195 Nfdc35204645046e5a9a27a84b94c60d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Treatment Outcome
197 rdf:type schema:DefinedTerm
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
202 schema:name Oncology and Carcinogenesis
203 rdf:type schema:DefinedTerm
204 sg:journal.1105545 schema:issn 1068-9265
205 1534-4681
206 schema:name Annals of Surgical Oncology
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.01032321717.09 schema:affiliation grid-institutes:grid.48336.3a
210 schema:familyName Kranda
211 schema:givenName Karen
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09
213 rdf:type schema:Person
214 sg:person.01306041342.14 schema:affiliation grid-institutes:grid.48336.3a
215 schema:familyName Temeck
216 schema:givenName Barbara K.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14
218 rdf:type schema:Person
219 sg:person.014210640617.24 schema:affiliation grid-institutes:grid.94365.3d
220 schema:familyName Steinberg
221 schema:givenName Seth M.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24
223 rdf:type schema:Person
224 sg:person.0763326335.92 schema:affiliation grid-institutes:grid.48336.3a
225 schema:familyName Pass
226 schema:givenName Harvey I.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92
228 rdf:type schema:Person
229 sg:pub.10.1007/bf00194542 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052242345
230 https://doi.org/10.1007/bf00194542
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/bf00255753 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040954660
233 https://doi.org/10.1007/bf00255753
234 rdf:type schema:CreativeWork
235 grid-institutes:grid.48336.3a schema:alternateName Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA
236 schema:name Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA
237 rdf:type schema:Organization
238 grid-institutes:grid.94365.3d schema:alternateName the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
239 schema:name the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
240 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...